X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WYETH LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WYETH LTD DR. REDDYS LAB/
WYETH LTD
 
P/E (TTM) x 34.9 27.7 126.0% View Chart
P/BV x 3.4 5.3 64.0% View Chart
Dividend Yield % 0.8 1.3 62.0%  

Financials

 DR. REDDYS LAB   WYETH LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
WYETH LTD
Mar-13
DR. REDDYS LAB/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs3,3971,044 325.2%   
Low Rs2,560818 313.0%   
Sales per share (Unadj.) Rs856.5298.6 286.9%  
Earnings per share (Unadj.) Rs78.057.2 136.2%  
Cash flow per share (Unadj.) Rs139.958.4 239.5%  
Dividends per share (Unadj.) Rs20.0017.00 117.6%  
Dividend yield (eoy) %0.71.8 36.8%  
Book value per share (Unadj.) Rs739.8249.5 296.6%  
Shares outstanding (eoy) m165.7422.72 729.5%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.53.1 111.5%   
Avg P/E ratio x38.216.3 234.8%  
P/CF ratio (eoy) x21.315.9 133.5%  
Price / Book Value ratio x4.03.7 107.8%  
Dividend payout %25.729.7 86.4%   
Avg Mkt Cap Rs m493,63221,157 2,333.2%   
No. of employees `00022.70.5 4,610.0%   
Total wages/salary Rs m31,068400 7,767.0%   
Avg. sales/employee Rs Th6,259.013,787.4 45.4%   
Avg. wages/employee Rs Th1,369.8813.0 168.5%   
Avg. net profit/employee Rs Th569.72,643.3 21.6%   
INCOME DATA
Net Sales Rs m141,9616,783 2,092.8%  
Other income Rs m1,715353 486.4%   
Total revenues Rs m143,6767,136 2,013.4%   
Gross profit Rs m24,7221,617 1,528.6%  
Depreciation Rs m10,26627 38,594.0%   
Interest Rs m6346 11,527.3%   
Profit before tax Rs m15,5371,938 801.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m2,965632 469.0%   
Profit after tax Rs m12,9211,301 993.5%  
Gross profit margin %17.423.8 73.0%  
Effective tax rate %19.132.6 58.5%   
Net profit margin %9.119.2 47.5%  
BALANCE SHEET DATA
Current assets Rs m96,8376,984 1,386.6%   
Current liabilities Rs m84,1992,056 4,095.5%   
Net working cap to sales %8.972.6 12.3%  
Current ratio x1.23.4 33.9%  
Inventory Days Days7399 73.9%  
Debtors Days Days9824 408.0%  
Net fixed assets Rs m102,552244 41,977.9%   
Share capital Rs m829227 364.9%   
"Free" reserves Rs m121,7925,441 2,238.5%   
Net worth Rs m122,6215,668 2,163.4%   
Long term debt Rs m5,44925 21,796.0%   
Total assets Rs m218,1657,901 2,761.2%  
Interest coverage x25.5353.3 7.2%   
Debt to equity ratio x00 1,007.5%  
Sales to assets ratio x0.70.9 75.8%   
Return on assets %6.216.5 37.6%  
Return on equity %10.522.9 45.9%  
Return on capital %12.934.0 37.9%  
Exports to sales %54.60.2 25,028.2%   
Imports to sales %9.436.3 25.7%   
Exports (fob) Rs m77,52015 523,783.8%   
Imports (cif) Rs m13,2742,465 538.4%   
Fx inflow Rs m81,67015 537,302.6%   
Fx outflow Rs m26,3552,677 984.4%   
Net fx Rs m55,315-2,662 -2,077.9%   
CASH FLOW
From Operations Rs m21,444923 2,322.8%  
From Investments Rs m-18,404317 -5,807.5%  
From Financial Activity Rs m-3,692-481 767.6%  
Net Cashflow Rs m-1,144759 -150.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 7.2 490.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 30.4 50.3%  
Shareholders   75,885 21,978 345.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 24, 2018 09:21 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - SHASUN PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS